Sentences with phrase «chimeric antigen»

An interrelationship exists between viral - vector upstream and downstream bioprocessing strategies and those for other therapeutic platforms such as chimeric antigen receptor (CAR) T cells and induced pluripotent stem cells (iPSCs).

The new results — from trials for patients with advanced lymphoma, multiple myeloma, and pancreatic cancer — expand on Penn's work with chimeric antigen receptor (CAR) therapies, building on findings in patients with chronic lymphocytic leukemia and acute lymphoblastic leukemia dating back to the start of the first clinical trial in 2010.

In recent years, immunotherapies, such as those involving chimeric antigen receptor (CAR) T cells, have become increasingly promising approaches to non-small-cell lung cancer (NSCLC) treatment.

This process involves inserting a «chimeric antigen receptor (CAR),» a protein that binds to a cell - surface marker called CD19, found on many leukemic cells.

The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T - cell therapy to be tested in a clinical trial as a treatment for B - cell non-Hodgkin lymphomas.

Dr. Locke participated in the clinical trials that led to US Food and Drug Administration approval of a novel chimeric antigen receptor (CAR) T - cell therapy called axicabtagene ciloleucel.

The use of anti-CD19 chimeric antigen receptor T cells induced a nearly sixfold higher rate of complete response compared with historical outcomes in patients with refractory, aggressive non-Hodgkin lymphoma.

SAN DIEGO, March 28, 2017 (GLOBE NEWSWIRE)-- Invivoscribe ® Technologies Inc., a global company with decades of experience providing internationally standardized clonality and biomarker testing solutions for the fields of oncology, personalized molecular diagnostics ®, and personalized molecular medicine ®, reports that its next - generation sequencing (NGS) LymphoTrack ® Assay kits are being used by its LabPMM ® clinical laboratories, pharmaceutical partners, and cancer centers to identify and monitor chimeric antigen receptor T - cells (CAR - T) and engineered T - cell receptors in peripheral blood of subjects in support of immuno - therapeutic drug development and treatment regimen development for both hematologic and solid tumors.

They are equipped with special receptors called chimeric antigen receptors (CARs) that recognize specific proteins on cancer cells and eliminate those cells.

Chimeric antigen receptor T cells (CAR - Ts) are a type of engineered T cell used in adoptive T cell transfer.

mesothelin - specific chimeric antigen receptor (CAR) were capable of ablating large human mesothelioma tumors when infused into mice.

Dr. Payne and colleagues have devised an exceptionally innovative approach to re-engineer chimeric antigen receptor (CAR) T cells for therapy of autoimmunity.

One specific form of this approach, called chimeric antigen receptor (CAR) T cell therapy, has been shown in early clinical trials to be particularly effective at treating lymphoma.

One recent advance in cell - based therapies is the dramatic progress of chimeric antigen receptor T (CAR - T) cell therapies in the treatment of certain blood cancers.

Research into such therapies as chimeric antigen receptor T cells (CAR - T) cancer therapies and stem - cell regenerative medicines demand the isolation and purification of viable and functional target cells.

CAR = chimeric antigen receptor.

Tisagenlecleucel is a one - time injection of chimeric antigen receptor (CAR) T cells manufactured for an individual patient using their own cells.

CAR - T immunotherapy involves genetically outfitting a patient's immune cells with a new artificial gene, a chimeric antigen receptor (CAR), which allows the cells to recognize and attack specific cancer cells.

To produce CAR T - cells, doctors send a patient's blood to a lab where technicians isolate T - cells and engineer them to produce chimeric antigen receptors, or CARs.

In CAR T therapy, a person's own T cells — disease - fighting immune cells — are removed and sent to a lab where they are genetically re-engineered to produce chimeric antigen receptors (CARs) on their surface.

Richard Vague, the event's honorary chair, took the podium to acknowledge the vast achievements of the ACC, as did Lori Alf, a multiple myeloma patient of Edward Stadtmauer, MD, chief of Hematologic Malignancies, whose cancer is in remission after receiving chimeric antigen receptor (CAR) therapy.

Chimeric antigen receptor - modified T cells in chronic lymphoid leukemia.

Precious patient samples, contamination concerns, and limited product purification options have compelled manufacturers of cellular immunotherapies (iTx) such as chimeric antigen receptor T cells (CAR - T) and T - cell receptor (TCR) technologies toward the disposables industry.

In the proposed project, Dr. Lampi Hermanson will produce NK cells from stem cells, inserting a chimeric antigen receptor (CAR) with the capacity to recognize mesothelin cells, which is expressed in 70 % of ovarian cancer patients.

A research team led by Christine Brown, Ph.D., and a clinical team headed by Behnam Badie, M.D., has received a $ 12.8 million grant from the CIRM to fund a phase 1 chimeric antigen receptor (CAR) T cell trial targeting an aggressive brain cancer called malignant glioma, which includes glioblastoma.

T - cells can be programmed to recognise these by giving them genes for tailor - made receptors called chimeric antigen receptors (CARs).

Those findings are among results of six studies of investigational chimeric antigen receptor (CAR) T cells for both adult and pediatric leukemias, adult lymphomas, and ovarian cancer which will be presented during the 2016 American Society of Clinical Oncology Annual Meeting.

His laboratory has made several seminal contributions to the field of chimeric antigen receptors (CARs), from their conceptualization and optimization to their clinical translation for cancer immunotherapy.

The modified T cells contain a protein known as a chimeric antigen receptor (CAR), which is designed to target the CD19 protein found on the surface of B cells, including the cancerous B cells that characterize several types of leukemia and lymphoma.

Chimeric antigen receptor (CAR) T cell therapy, which edits a cancer patient's T cells to recognize their tumors, has successfully helped patients with aggressive blood cancers but has yet to show the ability to treat solid tumors.

The engineered cells contain an antibody - like protein known as a chimeric antigen receptor (CAR), which is designed to bind to a protein called CD19 found on the surface of B cells, including the cancerous B cells that characterize several types of leukemia.

Over the past two years, investigators from the Perelman School of Medicine at the University of Pennsylvania have reported results from a human trial in GBM using chimeric antigen receptor (CAR) T cell therapy, through which patients» own T cells were engineered to track down and kill cancer cells that express a tumor - specific protein known as EGFRvIII.

More specifically, tisagenlecleucel is a type of chimeric antigen receptor T cell (CAR - T) therapy, a technique pioneered by immunologist Carl June and colleagues at the University of Pennsylvania.

Through gene therapy, researchers engineered blood - forming stem cells (hematopoietic stem / progenitor cells, or HSPCs) to carry chimeric antigen receptor (CAR) genes to make cells that can detect and destroy HIV - infected cells.

They will examine the safety and feasibility of administering cancer - fighting chimeric antigen receptor (CAR) T cells that have been reprogrammed to target the CD22 protein expressed by some leukemia cells.

The CARs that drive these treatments are custom - designed proteins called chimeric antigen receptors.

Chimeric antigen receptor (CAR) T - cell therapies utilize a patient's own T cells that have been genetically engineered to bind to a specific antigen on target cancer cells.

T cells genetically engineered to make the chimeric antigen receptor can recognize and target tumor cells.

Fifteen years ago, Campana helped develop the chimeric antigen receptor that's used in Kymriah today.

Those proteins, called chimeric antigen receptors, recognize the cancer cells in the patient's body.

We designed chimeric antigen receptor (CAR) T cells that specifically target podoplanin (PDPN), a key protein for the progression of solid tumors, including GBM.»

A transformative cancer therapy based on modified immune cells has lured doctors, companies, and patients alike, but many are hitting a frustrating roadblock: generating enough of these chimeric antigen receptor (CAR)- T cells to meet surging demand.

No. 4: CAR - T takes a backseat Research into chimeric antigen receptor T - cell (CAR - T) therapy has captured the attention of investors over the past two years, but safety risks could emerge as trial sizes increase, and that could help shift attention to other promising anti-cancer approaches, including NantKwest's (NASDAQ: NK) natural killer cell approach and soon - to - IPO Editas» CRISPR / Cas approach.

While that might not sound like a big deal, investors probably liked what Ji would be discussing: Sorrento's chimeric antigen receptor T cell (CAR - T) technology.

At this time, trials and plans for its other CD19 - directed chimeric antigen receptor (CAR) T - cell product candidates, including JCAR017, are not affected.

JCAR015 is a CD19 - directed chimeric antigen receptor technology (CAR - T) product candidate that has been under study in ROCKET in adult patients with relapsed or refractory B - cell acute lymphoblastic leukemia.

In December 2016, the New England Journal of Medicine published a study demonstrating that a chimeric antigen receptor therapy (CAR - T) caused glioblastoma regression.

Santa Monica, California - based Kite is developing chimeric antigen receptor T - cell therapy, known as a CAR T, which harnesses the body's own immune cells to recognize and attack malignant cells.

US - based pharmaceutical company Gilead Sciences entered the chimeric antigen receptor (CAR) T - cell therapy business through its acquisition of Kite Pharma, and Australian biopharma company CSL Behring acquired US - based Calimmune, a company that develops clinical - stage gene therapy solutions.

The race to become the first company with a chimeric antigen receptor T - cell (CAR - T) cancer therapy on the market has entered its final leg, and Kite Pharma now appears to have a big advantage.